Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Significant Decrease in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 148,911 shares, a decrease of 30.5% from the March 15th total of 214,196 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average trading volume of 50,346 shares, the days-to-cover ratio is presently 3.0 days.

Insider Buying and Selling at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost purchased 50,000 shares of Cocrystal Pharma stock in a transaction dated Friday, February 6th. The shares were bought at an average cost of $0.95 per share, for a total transaction of $47,500.00. Following the purchase, the director owned 1,888,551 shares in the company, valued at approximately $1,794,123.45. This trade represents a 2.72% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 28.14% of the company’s stock.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC purchased a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. 6.72% of the stock is owned by institutional investors and hedge funds.

Cocrystal Pharma Price Performance

COCP stock traded down $0.03 during midday trading on Wednesday, reaching $1.50. 315,387 shares of the stock were exchanged, compared to its average volume of 2,112,357. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67. The company has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.07. The stock has a market capitalization of $20.69 million, a PE ratio of -1.90 and a beta of 1.18.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Tuesday, March 31st. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. As a group, analysts anticipate that Cocrystal Pharma will post -1.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.